A Phase Ib/II combination trial of acalabrutinib with rituximab, cyclophosphamide, doxorubicin,vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Acalabrutinib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ACCEPT
- 24 Oct 2019 Planned End Date changed from 31 Dec 2021 to 28 Feb 2022.
- 24 Oct 2019 Planned primary completion date changed from 31 Aug 2019 to 31 Jan 2020.
- 05 Apr 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Aug 2019.